Search results
Samsung Biologics is a fully integrated CDMO with qualified and highly innovative contract development, contract manufacturing, and biosafety testing services.
- About Us
Samsung Biologics is a fully integrated, end-to-end CDMO...
- Our Services
Samsung Biologics offers customized solutions to optimize...
- Careers
Samsung Biologics. Who we want. Talent with vision and goals...
- Sustainability
Samsung Biologics is pursuing its mission to create a better...
- Investors
Samsung Biologics is committed to delivering solid financial...
- Newsroom
High-flying Samsung Biologics inks $1B production pact with...
- Manufacturing Services
Samsung Biologics is a reliable partner for seamless tech...
- Quality
Samsung Biologics is committed to the following: We strive...
- About Us
Samsung Biologics Co., Ltd. is a South Korean biotechnology company headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, it provides contract development and manufacturing (CDMO) services to the biopharmaceutical industry.
Mar 31, 2023 · Samsung Biologics offers end-to-end solutions from cell line development to final aseptic fill/finish for biopharmaceutical products. Learn about its vision, mission, and values as a trusted partner for Better Life for humanity.
Samsung Biologics America (SBA) offers trusted services to clients and industry partners in the biopharmaceutical industry. SBA has offices in San Francisco, New Jersey and Boston, where it provides CDO, R&D and other support.
6 days ago · Samsung Biologics announced July 2 that it has signed a $1.06 billion contract with a U.S.-based pharmaceutical company for the contract manufacturing of biopharmaceuticals. This is the largest contract ever secured by a South Korean biotech company and represents 42% of Samsung Biologics’ total orders from last year.
Samsung Biologics is a fully integrated CDMO offering state-of-the-art contract development and manufacturing services.
Jul 5, 2023 · South Korea's Samsung Biologics announced on Tuesday two deals with Pfizer worth a combined $897 million to manufacture products for the U.S. pharmaceutical giant.